There is research on this stock available only to PRO subscribers.
Thu, May. 15, 9:35 AM
Mon, Apr. 7, 3:31 PM
- The China Food and Drug Administration halts the sale of Tianyin Pharmaceuticals' (TPI +3.1%) liver drug Hugan as it performs due diligence on its price and GMP before awarding the firm the right to sell the product in Zhejiang province. The agency's action is a customary part of its regulatory process.
- The product contributes ~$600K in annual sales.
- The company expects the examination to be over in April and sales will recommence.
Wed, Mar. 5, 12:45 PM
Feb. 14, 2013, 6:18 AM
Nov. 15, 2012, 6:30 AM
Sep. 28, 2012, 2:32 PMTianyin Pharma (TPI +12.5%) trades higher today after upping FY13 guidance, despite reporting lower FY 2012 results. Revenue came in at $69.6M, down from $95.2M a year ago. The company attributes the Y/Y decline to generic pricing pressure under the ongoing healthcare reform, but sees momentum going forward. For FY 2013, it expects revenue to be between $75M and $80M, higher than previous estimates. ( PR )
Dec. 3, 2009, 9:00 AM
Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.
TPI vs. ETF Alternatives
Tianyin Pharmaceutical Co, Inc. is engaged in the development, manufacturing, marketing and sales of patented biopharmaceutical medicines, branded generics, modernized traditional Chinese medicines, and other pharmaceuticals in China.
Other News & PR